Get started Log in

ENTX — Entera Bio Share News

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMid CapMomentum Trap

Market Cap
$525.25m
Enterprise Value
$513.94m
Revenue
$0.04m

Entera Bio surges 40% on positive topline data for osteoporosis drug
23/06/2021 14:15
Brief: Entera Bio Announces Excellent Topline Phase 2 BMD Data For EB613
23/06/2021 14:08
Receives Foundational Patent For Its Oral Pth Using Its Platform Oral Protein Delivery Technology In European Union
17/06/2021 13:03
Entera Bio Ltd reports results for the quarter ended in March - Earnings Summary
20/05/2021 15:46
Brief: Entera Bio Reports Q1 Revenue Of $157,000
20/05/2021 13:29
Brief: Entera Appoints Ramesh Ratan As Chief Financial Officer
15/04/2021 13:35
Brief: New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone
06/04/2021 13:40
Brief: Entera Bio Announces Operating And Financial Results For Q4 And Year Ended December 31, 2020
18/03/2021 12:37
NASDAQ RESUMED AT 10:05 AM
12/03/2021 15:05
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:49 AM
12/03/2021 14:50
U.S. RESEARCH ROUNDUP-Endo International, Lennar, Uber Technologies
12/03/2021 07:19
Entera Bio: Nearly triples on positive interim data from osteoporosis treatment study
11/03/2021 14:42
Brief: Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data
11/03/2021 13:57
Brief: Entera Bio Announces Publication Of Phase 2 Hypoparathyroidism Study In The Journal Of Bone And Mineral Research
25/02/2021 14:40
Brief: Entera Bio Initiates New Research Program For Oral Glp-2
08/02/2021 13:51
Brief: Entera Bio Issues Letter To Shareholders
11/01/2021 14:39
Entera Bio: Up on FDA nod for U.S. trial of osteoporosis treatment
10/12/2020 17:55
Brief: Entera Bio Reports FDA Approval Of IND Application For EB613
10/12/2020 14:54
Brief: Entera Bio Appoints Spiros Jamas As Chief Executive Officer
30/11/2020 21:13
Brief: Entera Bio Ltd Announces Third Quarter 2020 Financial Results And Provides Clinical Update
19/11/2020 11:44